Literature DB >> 9185122

Oral famotidine: a potential treatment for children with autism.

L A Linday1.   

Abstract

Famotidine (Pepcid, a histamine-2 receptor blocker, is marketed for the treatment of peptic ulcer disease, gastroesophageal reflux, and the treatment of pathological hypersecretory conditions, including the Zollinger-Ellison syndrome. Recent reports indicate that it is also effective in relieving the deficit (or withdrawal) symptoms of adults with schizophrenia. Autism, a neuropsychiatric disorder which presents within the first few years of life, is defined by deficient social interaction, communication, language, play, and a markedly restricted repertoire of activities and interests. Similarities between the deficit symptoms of schizophrenia and the social deficit symptoms of autism suggest the hypothesis that famotidine may be useful in treating children with autism. Histamine serves as a neurotransmitter and neuromodulator in the brain. H2-receptors in the brain predominantly transmit inhibitory signals; when these receptors are stimulated in animals, spontaneous activity and exploratory behavior decrease; blockade of H2-receptors would therefore be expected to reverse this inhibition.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185122     DOI: 10.1016/s0306-9877(97)90032-3

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  6 in total

1.  Pharmacotherapy of target symptoms in autistic spectrum disorders.

Authors:  P J Santosh; G Baird
Journal:  Indian J Pediatr       Date:  2001-05       Impact factor: 1.967

Review 2.  Gastrointestinal factors in autistic disorder: a critical review.

Authors:  Craig A Erickson; Kimberly A Stigler; Mark R Corkins; David J Posey; Joseph F Fitzgerald; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2005-12

3.  Effects of an H3R antagonist on the animal model of autism induced by prenatal exposure to valproic acid.

Authors:  Diego Baronio; Kamila Castro; Taylor Gonchoroski; Gabriela Mueller de Melo; Gustavo Della Flora Nunes; Victorio Bambini-Junior; Carmem Gottfried; Rudimar Riesgo
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

4.  Histaminergic system in brain disorders: lessons from the translational approach and future perspectives.

Authors:  Diego Baronio; Taylor Gonchoroski; Kamila Castro; Geancarlo Zanatta; Carmem Gottfried; Rudimar Riesgo
Journal:  Ann Gen Psychiatry       Date:  2014-11-18       Impact factor: 3.455

Review 5.  Exploring the Validity of Valproic Acid Animal Model of Autism.

Authors:  Darine Froy N Mabunga; Edson Luck T Gonzales; Ji-Woon Kim; Ki Chan Kim; Chan Young Shin
Journal:  Exp Neurobiol       Date:  2015-12-16       Impact factor: 3.261

Review 6.  Role of Neuroinflammation in Autism Spectrum Disorder and the Emergence of Brain Histaminergic System. Lessons Also for BPSD?

Authors:  Nermin Eissa; Adel Sadeq; Astrid Sasse; Bassem Sadek
Journal:  Front Pharmacol       Date:  2020-06-16       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.